Mylan
1000 Mylan Boulevard
Canonsburg
Pennsylvania
15317
United States
Tel: 724-514-1800
Website: http://www.mylan.com/
About Mylan
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, Mylan innovates to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership
YEAR FOUNDED:
1961
LEADERSHIP:
Founders: Milan Puskar, and Don Panoz
CEO: Heather Bresch
CFO: Neil Dimick
PRODUCTS:
All Products
991 articles about Mylan
-
Mylan Inc. Announces Change in Board Leadership
5/7/2009
-
Mylan Inc.'s Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
4/20/2009
-
Mylan Inc. Declares Quarterly Preferred Stock Dividend
4/16/2009
-
Mylan Inc. Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
4/14/2009
-
Andrew G. Cuneo Joins Mylan Inc. as Vice President of Global Business Development
4/13/2009
-
Mylan Inc. and Schering-Plough Corporation Settle Clarinex Patent Lawsuit
4/8/2009
-
Mylan Inc. Execs Get 41% Raise; CEO Takes Company Jet on Vacation for "Security" Reasons
4/1/2009
-
Mylan Inc. to Pay $133 Million for Rest of Matrix Laboratories Limited
3/27/2009
-
Shire plc Extends Fosrenol Lawsuit to Mylan Inc.
3/20/2009
-
Mylan Inc.'s Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
3/12/2009
-
Mylan Inc.'s Matrix Laboratories Limited Receives World Health Organization Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
2/25/2009
-
Mylan Inc. Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
2/20/2009
-
Mylan Inc. Announces Transition of Chief Financial Officer
2/20/2009
-
Mylan Inc. Vice Chairman and Chief Executive Officer to Ring The NASDAQ Stock Market Opening Bell
2/19/2009
-
Mylan Inc. Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
2/19/2009
-
Barr Laboratories, Mylan Inc. Plan Generics of Shire plc's Fosrenol Drug
2/9/2009
-
Mylan Inc. Receives FDA Approval for First-to-File Generic Depakote(R) ER
1/30/2009
-
Mylan Inc. Declares Quarterly Preferred Stock Dividend
1/30/2009
-
Mylan Inc. Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
1/28/2009
-
FDA Approves Mylan Inc.'s Generic Version of Prilosec
1/23/2009